Cost estimations
| Drug acquisition cost * | ||||||||
| Drug | Commentary | Unit cost (€) | Cost first year (€) † | Cost following years (€) † | Ref | |||
| Adalimumab 40 mg | Cost of one syringe of Humira 40 mg | 494.61 | 14 830 | 12 860 | 19 | |||
| Golimumab 50 mg | Cost of one syringe of Simponi 50 mg | 1074.55 | 18 267 | 12 895 | 19 | |||
| Golimumab 100 mg | Cost of one syringe of Simponi 100 mg | 2149.11 | 19 | |||||
| Infliximab 100 mg | Cost of one phial of Inflectra 100 mg | 423.04 | 11 845 | 9624 | 19 | |||
| Vedolizumab 300 mg | Cost of one phial of Entyvio 300 mg | 3334.29 | 26 674 | 21 673 | 19 | |||
| Tofacitinib 5 mg | Cost of one table Xeljanz 5 mg | 14.16 | 20 680 | 20 680 | 19 | |||
| Follow-up costs (units/ 8 weeks' cycle) ‡ | ||||||||
| Health state | Biochemical profile | Day hospital | Endoscopy | Emergency endoscopy | Specialist | Surgery costs | Surgery complication | Ref |
| Active colitis | 1 | 0.05 | 0.31 | 0.12 | 1 | 0 | 0 | 19 |
| Induction | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 19 |
| Remission | 0.5 | 0.05 | 0.03 | 0 | 0.31 | 0 | 0 | 19 |
| Response | 0.6 | 0.05 | 0.08 | 0.04 | 0.69 | 0 | 0 | 19 |
| Surgery | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 20 21 |
| Surgery complication | 0.5 | 0.02 | 0.1 | 0.1 | 0.27 | 0 | 1 | 20 21 |
| Surgery remission | 0.23 | 0 | 0.19 | 0.08 | 0.23 | 0 | 0 | 20 21 |
| Follow-up costs values (unit costs obtained from the Aragon Public Hospitals accounting system 2018) | ||||||||
|
Baseline value
mean (SD) | PSA distribution § | Ref | ||||||
| Biochemical profile | 125.81 (1) | GAMMA (α=15 8280.16; λ=125.81) | 19 | |||||
| Day hospital | 112.83 (1) | GAMMA (α=12 7300.61; λ=112.83) | 19 | |||||
| Endoscopy | 307.08 (1) | GAMMA (α=94 2980.13; λ=307.08) | 19 | |||||
| Emergency endoscopy | 307.08 (1) | GAMMA (α=94 2980.13; λ=307.08) | 19 | |||||
| Hospitalisation | 6508 (7.02) | GAMMA (α=0.86; λ=1.32e-04) | 19 | |||||
| Specialist | 49.95 (1) | GAMMA (α=24940.50; λ=49.95) | 19 | |||||
| Surgery | 10 290 (6543) | GAMMA (α=2.47; λ=2.40e-04) | 19 | |||||
| Surgery complication | 7968.53 (11.83) | GAMMA (α=0.45; λ=5.69e-05) | 19 | |||||
| Adverse events, costs 2018 ¶ | ||||||||
| Adverse events, costs 2018 ¶ |
Baseline value
mean (SD) | PSA distribution § | Ref | |||||
| Appendicitis | 3923.64 (2,539.08) | GAMMA (α=2.39; λ=6.09e-04) | 35 | |||||
| Gastroenteritis | 2596.2 (2,264.76) | GAMMA (α=1.31; λ=5.06e-04) | 35 | |||||
| Infusion reaction | 3316.68 (4,331.88) | GAMMA (α=0.59; λ=1.77e-04) | 35 | |||||
| Pancreatitis | 3335 (2,375) | GAMMA (α=1.97; λ=5.91e-04) | 35 | |||||
| Sinusitis | 2334.96 (2,289) | GAMMA (α=1.04; λ=4.45e-04) | 35 | |||||
| Serious infection | 4218 (5,570) | GAMMA (α=0.57; λ=1.36e-04) | 35 | |||||
*Regimen treatments are shown in table 1.
†It is considered the weight of 76.2 Kg.
‡Units of resources consumed in one cycle, length of 8 weeks.
§PSA distribution parameters used in the model.
¶Severe and serious adverse events were included depending on their frequency of appearance based on their SmPC.
PSA, Probabilistic sensitivity analysis; Ref, Reference.